PILA PHARMA

PILA PHARMA We pioneer a new oral treatment for , and , based on inhibition 💊 We are developing a new diabetes drug

🎯 "We're in a good position to soon enter mid-stage clinical trials in people living with , so its going to be an excit...
02/09/2026

🎯 "We're in a good position to soon enter mid-stage clinical trials in people living with , so its going to be an exciting next period!"

- CEO Gustav H. Gram

🎥 Together with Direkt Studios we hosted a live review of H1 and commented on the recent news of regulatory approval for a new longer clinical trial to explore higher doses, including the upcoming development milestones for PILA PHARMA!

If you missed the updates last week after the release of our H1 report, you can find it all online.
Link to the this particular interview is in the comments!

: PILA PHARMA PUBLISHES INTERIM REPORT (1 JANUARY – 30 JUNE 2026)Please find the H1 report here: https://pilapharma.com...
27/08/2026

: PILA PHARMA PUBLISHES INTERIM REPORT
(1 JANUARY – 30 JUNE 2026)

Please find the H1 report here:https://pilapharma.com/Image/Reports/Interim_Report_First_Half_Year_2026_Pila-Pharma.pdf

Invitation to H1 report webcast & CEO comments on CTA approval 📖 On Thursday, 27 August we'll be hosting a live webca...
24/08/2026

Invitation to H1 report webcast & CEO comments on CTA approval 📖

On Thursday, 27 August we'll be hosting a live webcast together with Direkt Studios in relation to the release of our financial report for the first half of 2026! 🎥

The webcast commences at 11:00 CET with CEO Gustav H. Gram elaborating the report and the recent news of obesity CTA approval from European Medicines Agency of PILA PHARMA's oral antagonist! 💊

The link is already running and can be bookmarked here.
Link to the webcast: https://www.youtube.com/live/FjVmquk8zq0

PILA PHARMA receives regulatory approval to conduct PP-CT04, a 12-week trial exploring the safety and efficacy of XEN-D0...
18/08/2026

PILA PHARMA receives regulatory approval to conduct PP-CT04, a 12-week trial exploring the safety and efficacy of XEN-D0501 in people living with !

Big news! PILA PHARMA has received permission to conduct its first ever clinical trial of 3 months duration with oral antagonist XEN-D0501!

The trial codenamed PP-CT04, is a two-part, randomised, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

The trial is designed to explore a within-subject dose titration approach to reach anticipated therapeutic plasma concentrations of XEN-D0501 not previously investigated.

You can find the full press release in the comments!

💡 "We need a more coherent unified structure and political framework for and , across Europe, not just locally" Today...
16/06/2026

💡 "We need a more coherent unified structure and political framework for and , across Europe, not just locally"

Today, PILA PHARMA and CEO Gustav H. Gram were part of a selected and curated group of 🧪 companies and 💰 that were invited for the Biotech Leadership Forum hosted by the Lifescience Group at Dansk Industri - DI together with - Dansk Biotek!

🌟 The programme included some great speakers CEO of Novo Nordisk Foundation, Mads Krogsgaard Thomsen and panelists Managing Director at Lundbeckfonden, Christian E. Elling, CEO at Innovation District CPH, Annemarie Munk Riis, Provost at Danmarks Tekniske Universitet - DTU, Christine Nellemann and CEO of Zealand Pharma, Adam Steensberg.

It was an interesting day to discuss our local danish, nordic and overall european frameworks - and possible/necessary improvements - for a thriving ecosystem that retains biotech and lifescience companies in Europe!

🌍 We look forward to engage and contribute further with our industry colleagues to shape a better future of biotech and lifescience in .

Thanks to Peder Søgaard-Pedersen and Morten Engsbye for the great event, and good to see many old acquaintances and meet new ones!

🙏 Jan Stenvang, Steen Klysner, Peter Horn Møller and many more.

💬 "Beyond the Horizon: Next-Generation GLP-1's, Alternatives & the Future of Diabetes Care and Metabolic Disorders" 🌟 Ea...
22/05/2026

💬 "Beyond the Horizon: Next-Generation GLP-1's, Alternatives & the Future of Diabetes Care and Metabolic Disorders" 🌟

Earlier this week our CEO Gustav H. Gram was invited to participate on a panel debate at LSX Nordic Congress in Copenhagen, to discuss the current and future developments in therapeutics and infrastructure around , and care! 💡

The main takeaways were:

🚨 is still an issue, but with more solutions coming the opportunities for patients and clinicians will only improve and costs will likely only go one way = down! The holy grail would/could be OTC products for everyday wishing to keep overweight at bay!

🏥 There will be many of patients with obesity and co-related disorders, so a vast array of treatments will be needed whether oral, subcutaneous and targeting different pathways to give based on patient needs!

🎯 Pathways that look beyond GLP1 are increasingly in favour - where the importance on profiles and patient where especially potent anti-inflammatory agents and agents promoting "healthy" that retains more muscle mass, could be the coming wave for partnerships.

Thanks a lot to and panelt participants from Yazen Health (Elin Skoglund), Atrogi (Hamza Bokhari), Novo Nordisk (Simon Regnéll) & SIGRID (Kasper Wickzén)

In PILA PHARMA we're grateful for the opportunity to speak at such events and are keen on voicing our opinion, concerns and views in future sessions!

💫 All in all the panel debate very much confirmed that the participating companies, including PILA PHARMA with its clinical stage oral antagonist will play a part in the future of care.

📖 AGM 2026 - the shareholders annual gathering 🌟 Earlier this week, PILA PHARMA held its annual general meeting at its o...
22/05/2026

📖 AGM 2026 - the shareholders annual gathering 🌟

Earlier this week, PILA PHARMA held its annual general meeting at its offices in Malmö, an annual opportunity for shareholders to meet and discuss with management and board around the status and future of the company! 💡

It was a meeting a good turnout of shareholders, coming with some interesting questions, discussions and great mingle time afterwards! 💬 We hope more shareholders will participate in future meetings and events!

The list of topics and decisions can be found in the press release, in the comments section 📚

08/05/2026

🚨 Reminder! Registration for the annual general meeting on 19 May: Today 08 May, is the last for shareholders registration if shares are held privately!

If you have shares registered by a custodian, registration is due by Tuesday 12 May! 🏦

If you're currently not a shareholder but wish to participate, today is thus the last day to take action! 🌟

💡 In both cases a notice of registration is also required to be sent to [email protected] by Tuesday 12 May!

If you are a shareholder but unable to attend, we highly recommend to sign a power of attorney (Fullmakt) and sent to Chairman of the Board, Dorte X. Gram, equally on [email protected].

All documents and more information can be found on the dedicated AGM webpage.
https://pilapharma.com/arsstamma-2026/

🚨 Reminder! Registration for the annual general meeting on 19 May: Today 08 May, is the last for shareholders registrati...
08/05/2026

🚨 Reminder! Registration for the annual general meeting on 19 May: Today 08 May, is the last for shareholders registration if shares are held privately!

If you have shares registered by a custodian, registration is due by Tuesday 12 May! 🏦

If you're currently not a shareholder but wish to participate, today is thus the last day to take action! 🌟

💡 In both cases a notice of registration is also required to be sent to [email protected] by Tuesday 12 May!

If you are a shareholder but unable to attend, we highly recommend to sign a power of attorney (Fullmakt) and sent to Chairman of the Board, Dorte X. Gram, equally on [email protected].

All documents and more information can be found on the dedicated AGM webpage.
https://pilapharma.com/arsstamma-2026/

🎤 UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT Redeye DIABETES DAY ON 06 MAYPILA PHARMA will have corporate ...
06/05/2026

🎤 UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT Redeye DIABETES DAY ON 06 MAY

PILA PHARMA will have corporate interviews and presentations at several locations today, May 06, 2026. Please find the links below!

🏥 06 May: Redeye Diabetes Day (in-person and online)
Stockholm, Sweden – 13:15 CEST
Link: https://www.redeye.se/events/1139709/redeye-theme-diabetes-4

💫 06 May: Direkt Studios Interview (Online Recording)
Stockholm, Sweden – Release Time TBA
Link: https://www.youtube.com/direktstudios

📚 06 May: Venture Partner Meeting (in-person, invite only)
Copenhagen, Denmark – 17:00 CEST
Link: https://portal.cvx.vc/event/cvx-partner-meeting-may-2026/

For those who missed the latest interview, it was conducted with BioStock - Connecting Innovation & Capital. Here our CEO Gustav Hanghøj Gram commented on the exposure results from the preclinical study, as well as the path forward to clinical trials in obesity.
Link: https://biostock.se/en/2026/04/pila-pharma-om-de-prekliniska-resultaten-och-vagen-framat/

Adress

Norra Vallgatan 72, 5 Place
Malmö
21122

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när PILA PHARMA postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till PILA PHARMA:

Genvägar

Dela

Typ